Harbour BioMed Appoints Dr. Adam Zong as President
This image was generated by AI and may not depict real events.
Harbour BioMed has appointed Dr. Adam Zong as its new President, bringing over 20 years of biopharma leadership experience. Dr. Zong will focus on developing a high-value portfolio and delivering transformative medicines.
Harbour BioMed has appointed Dr. Adam Zong as its new President. Dr. Zong has over 20 years of experience in global biopharma leadership, with a strong track record in portfolio strategy, commercial operations, and business development. He previously served as Principal Consultant at Arc Nouvel Clinical Development Consulting and as the founding CEO of Hengrui Therapeutics U.S. Dr. Zong will focus on further developing Harbour BioMed's portfolio and enhancing its global partnerships. Harbour BioMed is a global biopharmaceutical company committed to discovering and developing novel antibody therapeutics. The company has a robust pipeline and proprietary antibody technology platforms.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.